Could fewer doses of this prostate cancer drug be just as good?
NCT ID NCT06200103
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase II trial is testing whether giving 5 cycles of the radioactive drug Lu-177 PSMA-617 works as well as the standard 6 cycles for men with metastatic castration-resistant prostate cancer. The goal is to see if a shorter treatment course can control the cancer just as effectively while reducing side effects. About 236 participants will be randomly assigned to either stop after 5 cycles or continue to 6, and researchers will track how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lu 177 vipivotide tetraxetan (177Lu-PSMA-617)
- What this could lead to
- If successful, this could show that fewer treatment cycles are just as effective, reducing side effects and time spent on therapy for patients with advanced prostate cancer.
- What could go wrong
- This is a phase II trial with 236 participants, so results are still preliminary. The treatment pause might lead to faster disease progression in some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?
- Targeted radiation plus hormone therapy may slow Low-Volume prostate cancer spread